Sage Therapeutics' Zulresso (brexanolone) Receives FDA's Approval for Postpartum Depression (PPD)
Shots:
- The approval is based on three clinical studies assessing Zulresso (brexanolone) vs PBO in women with moderate to severe PPD + ≤6 mos. postpartum at screening aged 18 to 45yrs.
- The three clinical study results: met 1EPs; reduction in Hamilton Rating Scale for Depression (HAM-D) score; reduction in depressive symptoms within a day; maintained effect through the 30-day follow-up
- Zulresso (brexanolone- IV) is an allosteric modulator of GABAA receptor and has received FDA’s PR- BT designation & EMA’s PRIME designation for PPD
Click here to read full press release/ article | Ref: Sage Therapeutics | Image: Third Rock Ventures
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com